Ravulizumab: all 35 studies that test it

Page 1 of 1. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)RecruitingNCT07596784Phase 3
• Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)RecruitingNCT07557420Phase 3
• Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUSRecruitingNCT07308574Phase 4
• A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With RavulizumabRecruitingNCT07221838Phase 4
• Study of Ravulizumab in Pediatric Participants With Primary IgANRecruitingNCT07024563Phase 3
• Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSDRecruitingNCT07010302Phase 4
• Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney TransplantationRecruitingNCT06830798Phase 3
• Ravulizumab in Pregnancies Complicated by Severe Hypertensive DisordersRecruitingNCT06333652Phase 2
• Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedNCT06578949Phase 3Results posted
• A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult ParticipantsCompletedNCT05288829Phase 1Results posted
• A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese ParticipantsCompletedNCT05288816Phase 1Results posted
• A Study of Multiple Doses of ALXN1210 in Healthy Adult ParticipantsCompletedNCT05288673Phase 1Results posted
• A Study of a Single Dose of ALXN1210 in Healthy ParticipantsCompletedNCT05288660Phase 1Results posted
• Ravulizumab Versus Placebo in Adult Participants With DermatomyositisTerminatedNCT04999020Phase 2/3Results posted
• Ravulizumab in Thrombotic Microangiopathy Associated With a TriggerTerminatedNCT04743804Phase 3Results posted
• Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)TerminatedNCT04564339Phase 2Results posted
• Study of Ravulizumab in Pediatric Participants With HSCT-TMACompletedNCT04557735Phase 3Results posted
• Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe PneumoniaTerminatedNCT04369469Phase 3Results posted
• Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose EculizumabCompletedNCT04320602Phase 4Results posted
• An Efficacy and Safety Study of Ravulizumab in ALS ParticipantsTerminatedNCT04248465Phase 3Results posted
• An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSDCompletedNCT04201262Phase 3Results posted
• Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia GravisCompletedNCT03920293Phase 3Results posted
• Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With EculizumabCompletedNCT03748823Phase 3Results posted
• A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal HemoglobinuriaCompletedNCT03406507Phase 3Results posted
• Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)CompletedNCT03131219Phase 3Results posted
• Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)CompletedNCT02949128Phase 3Results posted
• Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedNCT02605993Phase 2Results posted
• Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedNCT02598583Phase 1/2Results posted
• Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)Active, not recruitingNCT06291376Phase 3
• ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKETerminatedNCT05746559Phase 3
• Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia GravisActive, not recruitingNCT05644561Phase 3
• Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSDActive, not recruitingNCT05346354Phase 2/3
• Ravulizumab and COVID-19Status unknownNCT04570397Phase 3
• Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell TransplantCompletedNCT04543591Phase 3
• mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)Status unknownNCT04390464Phase 4

← Ravulizumab overview